Omnicom Group Inc. Stock Rises Tuesday, Outperforms Market

Apellis Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

APLS Apellis Pharmaceuticals Inc

AMD Advanced Micro Devices Inc

OTIS Otis Worldwide Corp

GME GameStop Corp

ECF Ellsworth Growth and Income Fund Ltd

SILK Silk Road Medical Inc

HLVX Hillevax Inc

AIZ Assurant Inc

NOTV Inotiv Inc

MYD BlackRock MuniYield

Health Care : Biotechnology | Small Cap Growth

Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Omnicom Group Inc. Stock Rises Tuesday, Outperforms Market

5:14 pm ET November 22, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Omnicom Group Inc. (OMC) advanced 2.00% to $78.10 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.36% to 4,003.58 and the Dow Jones Industrial Average rising 1.18% to 34,098.10. Omnicom Group Inc. closed $13.51 below its 52-week high ($91.61), which the company reached on February 10th.

The stock underperformed when compared to some of its competitors Tuesday, as Publicis Groupe S.A. ADR (PUB.FR) rose 2.73% to $16.38 and Interpublic Group of Cos. (IPG) rose 3.11% to $33.82. Trading volume (856,569) remained 699,486 below its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 22, 2022.

(END) Dow Jones Newswires

November 22, 2022 17:14 ET (22:14 GMT)